Medicover AB (publ) provides diagnostic and healthcare services in Germany, Romania, Ukraine, Poland, Belarus, Moldova, Serbia, Turkey, Georgia, Bulgaria, India, and Hungary.
Reasonable growth potential with mediocre balance sheet.
Share Price & News
How has Medicover's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: MCOV B's share price has been volatile over the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: MCOV B exceeded the Swedish Healthcare industry which returned -20% over the past year.
Return vs Market: MCOV B exceeded the Swedish Market which returned -10.3% over the past year.
Price Volatility Vs. Market
How volatile is Medicover's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 week ago | Simply Wall StA Sliding Share Price Has Us Looking At Medicover AB (publ)'s (STO:MCOV B) P/E Ratio
2 weeks ago | Simply Wall StRobert Jochnick Is The Independent Director of Medicover AB (publ) (STO:MCOV B) And They Just Spent €2.5m On Shares
3 weeks ago | Simply Wall StHere's Why Medicover (STO:MCOV B) Can Manage Its Debt Responsibly
Is Medicover undervalued compared to its fair value and its price relative to the market?
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: MCOV B (SEK85.4) is trading above our estimate of fair value (SEK43.96)
Significantly Below Fair Value: MCOV B is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: MCOV B is poor value based on its PE Ratio (45.9x) compared to the Healthcare industry average (16.9x).
PE vs Market: MCOV B is poor value based on its PE Ratio (45.9x) compared to the Swedish market (14.1x).
Price to Earnings Growth Ratio
PEG Ratio: MCOV B is poor value based on its PEG Ratio (2.2x)
Price to Book Ratio
PB vs Industry: MCOV B is overvalued based on its PB Ratio (3.3x) compared to the SE Healthcare industry average (1.2x).
How is Medicover forecast to perform in the next 1 to 3 years based on estimates from 5 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: MCOV B's forecast earnings growth (21.2% per year) is above the savings rate (-0.4%).
Earnings vs Market: MCOV B's earnings (21.2% per year) are forecast to grow faster than the Swedish market (7.8% per year).
High Growth Earnings: earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: MCOV B's revenue (11.6% per year) is forecast to grow faster than the Swedish market (4.1% per year).
High Growth Revenue: MCOV B's revenue (11.6% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: MCOV B's Return on Equity is forecast to be low in 3 years time (14.7%).
How has Medicover performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: MCOV B has high quality earnings.
Growing Profit Margin: MCOV B's current net profit margins (2.7%) are lower than last year (3.7%).
Past Earnings Growth Analysis
Earnings Trend: MCOV B's earnings have grown significantly by 30.2% per year over the past 5 years.
Accelerating Growth: MCOV B's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: MCOV B had negative earnings growth (-8.5%) over the past year, making it difficult to compare to the Healthcare industry average (-25.3%).
Return on Equity
High ROE: MCOV B's Return on Equity (6.9%) is considered low.
How is Medicover's financial position?
Financial Position Analysis
Short Term Liabilities: MCOV B's short term assets (€215.8M) do not cover its short term liabilities (€281.7M).
Long Term Liabilities: MCOV B's short term assets (€215.8M) do not cover its long term liabilities (€378.1M).
Debt to Equity History and Analysis
Debt Level: MCOV B's debt to equity ratio (76.5%) is considered high.
Reducing Debt: MCOV B's debt to equity ratio has reduced from 122.1% to 76.5% over the past 5 years.
Debt Coverage: MCOV B's debt is well covered by operating cash flow (31.7%).
Interest Coverage: MCOV B's interest payments on its debt are well covered by EBIT (3.9x coverage).
Inventory Level: MCOV B has a high level of physical assets or inventory.
Debt Coverage by Assets: MCOV B's debt is not covered by short term assets (assets are 0.8x debt).
What is Medicover's current dividend yield, its reliability and sustainability?
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: MCOV B's dividend (0.65%) isn’t notable compared to the bottom 25% of dividend payers in the Swedish market (2.14%).
High Dividend: MCOV B's dividend (0.65%) is low compared to the top 25% of dividend payers in the Swedish market (6.55%).
Stability and Growth of Payments
Stable Dividend: MCOV B is not paying a notable dividend for the Swedish market, therefore no need to check if payments are stable.
Growing Dividend: MCOV B is not paying a notable dividend for the Swedish market, therefore no need to check if payments are increasing.
Current Payout to Shareholders
Dividend Coverage: MCOV B is not paying a notable dividend for the Swedish market.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of MCOV B's dividend in 3 years as they are not forecast to pay a notable one for the Swedish market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Fredrik Rågmark (56yo)
Mr. Fredrik Rågmark serves as the Group Chief Executive Officer of Medicover AB (publ). Mr. Rågmark has been employed with Medicover since 1996. He serves as Managing Director and Board Member of Kalvskär ...
CEO Compensation Analysis
Compensation vs Market: Fredrik's total compensation ($USD1.24M) is above average for companies of similar size in the Swedish market ($USD643.03K).
Compensation vs Earnings: Fredrik's compensation has increased by more than 20% whilst company earnings have fallen more than 20% in the past year.
|CEO & Director||no data||€1.12m||1.47% €166.9m|
|Chief Financial Officer||no data||no data||0.87% €99.0m|
|Chief Information Officer||0.42yr||no data||no data|
|Head of Investor Relations||no data||no data||no data|
|General Legal Counsel||no data||no data||0.0086% €981.5k|
|Chief Marketing Officer||no data||no data||no data|
|Group Human Resource Director||2.17yrs||no data||0.0020% €226.6k|
|Chief Operating Officer of Healthcare Services||4.08yrs||no data||0.39% €44.7m|
|Chief Operating Officer of Diagnostic Services||no data||no data||0.015% €1.7m|
|Chief Executive Officer of Medicover Foundation||no data||no data||no data|
Experienced Management: MCOV B's management team is considered experienced (2.2 years average tenure).
|CEO & Director||no data||€1.12m||1.47% €166.9m|
|Independent Director||13.17yrs||€40.00k||1.32% €150.4m|
|Independent Director||19.17yrs||€47.50k||0.059% €6.7m|
|Independent Director||19.17yrs||€40.00k||0.21% €24.1m|
|Independent Director||5.17yrs||€55.00k||no data|
|Independent Director||8.17yrs||€40.00k||2.19% €249.5m|
|Independent Director||3.17yrs||€47.50k||0.019% €2.1m|
Experienced Board: MCOV B's board of directors are seasoned and experienced ( 10.7 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: MCOV B insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Medicover AB (publ)'s company bio, employee growth, exchange listings and data sources
- Name: Medicover AB (publ)
- Ticker: MCOV B
- Exchange: OM
- Founded: 1995
- Industry: Health Care Services
- Sector: Healthcare
- Market Cap: kr11.387b
- Shares outstanding: 133.34m
- Website: https://www.medicover.com
Number of Employees
- Medicover AB (publ)
- Riddargatan 12A
- PO Box 55720
- Stockholm County
- 114 83
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|5M0B||DB (Deutsche Boerse AG)||Yes||Class B Shares||DE||EUR||May 2017|
|0RPS||LSE (London Stock Exchange)||Yes||Class B Shares||GB||SEK||May 2017|
|MCOV B||OM (OMX Nordic Exchange Stockholm)||Yes||Class B Shares||SE||SEK||May 2017|
|MCOVBS||BATS-CHIXE (BATS 'Chi-X Europe')||Yes||Class B Shares||GB||SEK||May 2017|
|MCVE.F||OTCPK (Pink Sheets LLC)||Yes||Class B Shares||US||USD||May 2017|
|MCVE.Y||OTCPK (Pink Sheets LLC)||UNSPONSRED ADS||US||USD||Oct 2018|
Medicover AB (publ) provides diagnostic and healthcare services in Germany, Romania, Ukraine, Poland, Belarus, Moldova, Serbia, Turkey, Georgia, Bulgaria, India, and Hungary. The company operates in two divisions, Diagnostic Services and Healthcare Services. Its diagnostic services consist of various tests, including allergy and autoimmune diagnostics, bacteriology, parasitology, biochemistry and immunochemistry, blood group diagnostics/transfusion medicine, tumour markers, clinical chemistry, cytology, haematology, histopathology, human genetics, hygiene, immunology and immunochemistry, infectious diseases, microbiology, molecular biology, and pharmacology/toxicology. The company offers outpatient and inpatient healthcare services, including fertility treatment, dental, elderly care, eye care, and skin and wellness services, as well as fitness and pharmacy solutions. It operates a network 95 clinical laboratories and 570 blood-drawing points in 10 countries; and 108 medical clinics, 23 fertility clinics, 17 hospitals, and 26 dental clinics. The company serves corporate and private customers, and patients. Medicover AB (publ) was founded in 1995 and is headquartered in Stockholm, Sweden.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/03/29 23:45|
|End of Day Share Price||2020/03/27 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.